Cingulate Inc. Common Stock CING
Analyst Ratings
- Consensus
- Buy — 3 Buy · 0 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $24.33 (+415.5% upside)
Key Stats
- Today's Range
- $4.05 – $4.93
- 50-Day Range
- $3.65 – $5.68
- 52-Week Range
- $3.16 – $11.89
- Volume
- 1.63 million shs
- Average Volume
- 185K shs
- Market Cap
- $56.11 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.02%
- Days to Cover
- 1.00
About Cingulate Inc. Common Stock
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Related Stocks
Compare head-to-head: CING vs LLY·CING vs JNJ·CING vs ABBV·CING vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.
